Use of statins is hypothesized to reduce colorectal cancer risk, but the evidence remains inconsistent. This may be partly explained by differential associations according to tumor location or molecular subtypes of colorectal cancer. We examined the association between statin use and colorectal cancer risk according to tumor location, KRAS mutation status, microsatellite instability (MSI) status, PTGS2 (cyclooxygenase-2, COX-2) expression, or CpG island methylator phenotype (CIMP) status in two large prospective cohort studies, the Nurses' Health Study and Health Professionals Follow-up Study. We 
These conflicting data may be in part related to the molecular heterogeneity of colorectal cancer. Cancers have distinct molecular alterations that may predict variation in clinical behavior or responsiveness to therapeutic agents as well as reflect differences in etiopathogenic mechanism. Statins inhibit generation of mevalonate, a precursor for synthesis of isoprenoids used in prenylation, a necessary post-translational step for functional KRAS. Similarly, statins have been hypothesized to be anti-inflammatory and in some studies and function synergistically with drugs with cyclooxygenase-2 (PTGS2, COX-2) activity such as aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) (4) (5) (6) (7) . In addition, clinical features and risk factors appear to vary according to microsatellite instability (MSI) status, CpG island methylator phenotype (CIMP) status, or tumor location (8) (9) (10) (11) (12) (13) . We therefore prospectively examined whether the association of statin use and colorectal cancer risk differed by KRAS mutation status, PTGS2 (COX-2) overexpression, MSI, or CIMP status. To our knowledge, no prior prospective studies have examined the association between statin use and colorectal cancer risk in relation to these tumor subtypes.
Cancer Research. 
Materials and Methods

Study population
The Nurses' Health Study (NHS) was established in 1976, when 121,700 female registered nurses who were 30 to 55 years of age returned a mailed questionnaire. The Health Professionals Follow-up Study (HPFS) was initiated in 1986 when 51,529 male health professionals aged 40 to 75 years returned a mailed questionnaire. Participants provided detailed information about their medical history, lifestyle, and risk factors for chronic diseases on biennial follow-up questionnaires. Because retrospective information on statin use was collected in 2000 to define statin use from 1994 forward in the NHS and from 1990 forward in the HPFS, we started follow-up in 1994 in the NHS and 1990 in the HPFS. This approach is consistent with prior analyses in these cohorts (14) (15) .
We excluded participants with missing data on statin use, had been previously diagnosed with cancer (except non-melanoma skin cancer), or had ulcerative colitis. As a result, 91,155 women in the NHS and 40,767 men in the HPFS were available for the analysis. Because there was no heterogeneity for the association of statin use and colorectal cancer between NHS and HPFS (P for heterogeneity >0.33 for each category of statin duration), we combined data from the two cohorts. The institutional review boards at Brigham and Women's Hospital and the Harvard School of Public Health approved this study.
Investigators blinded to participants' risk factor status reviewed medical records to confirm the diagnosis, and classify cancers according to anatomic location, and histologic types. A total of 1818 (952 in the NHS and 866 in the HPFS) cases were included in these analyses.
We retrieved, from the pathology departments of treating hospitals, available pathological specimens from participants diagnosed with colorectal cancer; 438 cases (51%) diagnosed in the HPFS and 449 cases (47%) in the NHS through 2006. The baseline characteristics of participants with colorectal cancer whose tumors we analyzed were similar to those of participants whose tumors we did not analyze (17) . We extracted DNA from paraffin-embedded tumor tissue sections and performed PCR and pyrosequencing targeted for KRAS codons 12 and 13 as previously described (18) . MSI status was assayed using 10 microsatellite markers (D2S123, D5S346, D17S250, BAT25, BAT26, BAT40, D18S55, D18S56, D18S67, and D18S487) (19) . If instability of markers was 30% or more, tumors were classified as MSI-high. We quantified DNA methylation in eight CIMP-specific promoters [CACNA1G, CDKN2A (p16), CRABP1, IGF2, MLH1, NEUROG1, RUNX3, and SOCS1] (20) (21) (22) . We defined CIMP-high if six or more of eight promoters were methylated, CIMP-low if one to five of eight promoters were methylated or CIMP-0 if none of eight were methylated. PTGS2 (COX-2) immunohistochemical assays were performed from incubating deparaffinized tissue sections as previously described (19, 23) . Compared to adjacent normal colonic mucosa, PTGS2 overexpression in tumor cells was classified using a standardized grading system (absent, weak, moderate, or strong). The pathologist classified staining of tumor cells as "absent" if 7 overexpression was categorized as PTGS2-negative, and moderate or strong was 
Statistical analysis
We calculated the relative risks (RRs) and 95% confidence intervals (95% CIs) associated with current statin use for each study using the Cox proportional hazards model (25) We used a competing-risk analysis using duplication-method Cox regression to examine whether the association between statin use and colorectal cancer differed by tumor sites or molecular subtypes (27) (28) . To test for the difference between tumor sites or molecular subtype, we compared the model fit that produces separate associations of statin use with different tumor sites or molecular markers to the model fit that assumed a common association using the likelihood ratio test. For the test for trend, participants were assigned the median value of statin duration and this variable was entered into the model as a continuous term. To examine whether the association for statin use varied by BMI, age, aspirin use, and alcohol intake, a likelihood ratio test was used to compare the model fit including the cross-product term of statin use and the specific modifier with the model fit without the cross-product term. All statistical tests were two-sided, and P values less than .05 were considered statistically significant. were more likely to be older, to use aspirin and multivitamins, to have ever had endoscopy, and to smoke in the past than those who did not use statins. Women who used statins were more likely to have higher BMI and less likely to drink alcohol. Compared to non-users, the prevalence of hypercholesterolemia (>=240 mg/dl) was higher among those men and women who began to use statins recently. In contrast, the prevalence of hypercholesterolemia was generally lower for men and women who had been on longterm statin treatment.
We documented 1818 colorectal cancers (952 in women and 866 in men) over 1,688,745 person-years of follow-up. We observed no significant association between the duration of statin use and overall risk of colorectal cancer ( Table 2 ). The age-adjusted RR of colorectal cancer was 0.85 (95% CI = 0.66 to 1.10) comparing 6 or more years of statin use to nonusers. When we additionally adjusted for use of aspirin and history of endoscopy, the RR was attenuated (multivariate RR = 0.97, 95% CI = 0.75 to 1.25).
Further adjustment for other covariates did not alter the association (multivariate RR = 0.97, 95% CI = 0.75 to 1.25).
We examined whether the association between statin use and colorectal cancer varied according to the anatomic site of the tumor ( Table 3) users had a significantly lower risk of rectal cancer (multivariate RR = 0.59, 95% CI = 0.41 to 0.84).
We confirmed that the lack of association between statin use and risk of colorectal cancer was consistent for cases with tissue available for analysis of molecular subtypes (multivariate RR = 0.92, 95% CI = 0.74 to 1.13) ( Table 4) 
Discussion
In this large, prospective study of two well-characterized, population-based cohorts, we found that statin use was not significantly associated with overall risk of colorectal cancer. However, we did observe a potential inverse association with risk of rectal cancer. In addition, our results suggest a possible differential association according to KRAS mutation status. To our knowledge, our study is the first to examine statin use and colorectal cancer according to molecular features of the tumor.
Substantial experimental data support a potential anti-cancer effect of statins. Statins induce apoptosis, inhibit cell proliferation, attenuate angiogenesis, and delay the metastatic process in in vitro and in vivo studies (29) (30) (31) (32) (33) . However, the results from human studies have not been consistent. Two systematic reviews observed modest reductions in colorectal cancer with statin use in case-control studies, but no clear association in randomized clinical trials or cohort studies (1-3, 34) . The lack of association between statin use and overall colorectal cancer we observed in this study is largely consistent with prior cohort studies. Generally, cohort studies may be less prone to the biases of case-control studies, which include differential sampling of cases and controls and differential recall of statin use or other confounding factors by cases compared with controls.
We did observe a potential inverse association between statin use and rectal cancer.
Because this finding is based on a relatively limited number of rectal cancer cases, these results should be interpreted cautiously. However, a test for heterogeneity of the association of statin use with colon or rectal cancer was statistically significant and a differential effect by site is biologically plausible. There are significant differences in risk factors, prevalence of specific molecular alterations, and gene expression levels that have been described according to cancer site (10, (35) (36) . A few studies have similarly NSAIDs (38-39, 42, 47-48) . In our study, we also did not observe a differential effect of statin use according to use of aspirin or expression of the pro-inflammatory enzyme PTGS2 (COX-2). However, it remains possible that statins may have anti-inflammatory effects that are independent of aspirin or COX-2 related pathways.
Finally, we also considered the effect of statins according to tumor subtypes defined by MSI or CIMP status. About 15% of sporadic colorectal cancers are MSI-H, arising primarily through epigenetic silencing of DNA mismatch repair proteins (49) . In contrast, the vast majority of sporadic colorectal cancers are MSS or MSI-L, developping through traditional chromosomal instability pathways. Colorectal cancer with CIMP-high status was associated with MSI and is well characterized as a major epigenetic marker in colorectal cancer (13, (21) (22) . However, in the present analysis, we did not observe a differential effect of statins on cancers subtyped by MSI or CIMP status.
Our study has several important strengths. First, our prospective cohort design minimized potential biases introduced by differential selection and recall found in casecontrol studies. Second, we collected detailed and updated information on statin use and other potential important confounding factors in a cohort with a high follow-up rate.
Third, because our participants were all health professionals, the accuracy of selfreported statin use is likely to be high and is more likely to reflect their actual use than prescription records. Finally, we examined the effect of statins on molecularly-defined as statin use, can be related to a specific somatic molecular change to gain insight into mechanism, provide evidence for causality, and potentially lead to more targeted approaches to prevention or therapy (8, 50) .
There are several limitations to our study. First, our study is observational. Thus, we cannot rule out the possibility of residual confounding. However, our overall findings are consistent with most prospective cohort studies. Moreover, our results suggesting an inverse association with KRAS-wildtype tumors has biological plausibility given our understanding of the effect of statins on the mevalonate pathway. Second, the prevalence of statin use, especially in the longer duration categories, was relatively low. However, as a prospective cohort study, our prevalence reflects secular trends in statin use (15% of current use) in the U.S. over the time period of the study (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) 2 in the HPFS), family history of colorectal cancer in parents and siblings (yes, no), history of endoscopy (yes, no), red meat intake (quintiles), alcohol intake (never, 0.1-9.9 g/d, 10-14.9 g/d, 15-29.9 g/d, ≥30 g/d), and total energy intake (continuous) †Among cases with available tissue for analysis of molecular markers ‡ For multivariate-adjusted RRs MSI, microsatellite instability; MSS, microsatellite stability.
